CDKV Holdings’s ALPS Medical Breakthroughs ETF SBIO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$167K Sell
2,580
-100
-4% -$5.48K 0.13% 79
2026
Q1
$140K Hold
2,680
0.12% 81
2025
Q4
$137K Buy
+2,680
New +$124K 0.11% 87

Other funds holding SBIO

CDKV Holdings's SBIO Position: Q2 2026 in Review

CDKV Holdings reduced its ALPS Medical Breakthroughs ETF (SBIO) stake by 3.7% in Q2 2026, selling an estimated $5.48K and leaving 2,580 shares worth $167K. The position accounts for 0.13% of the portfolio, ranked #79.

CDKV Holdings first reported a position in SBIO in Q4 2025 and has held it in 3 quarters since. 65 funds tracked by Wall St. Rank hold SBIO as of Q2 2026.

  • CDKV Holdings held 2,580 shares of ALPS Medical Breakthroughs ETF worth $167K as of Q2 2026.
  • CDKV Holdings sold 100 ALPS Medical Breakthroughs ETF shares in Q2 2026, an estimated $5.48K.
  • ALPS Medical Breakthroughs ETF made up 0.13% of CDKV Holdings's portfolio in Q2 2026, its #79 holding.
  • CDKV Holdings first reported a position in ALPS Medical Breakthroughs ETF in Q4 2025 and has held it in 3 quarters since.
  • 65 funds tracked by Wall St. Rank held ALPS Medical Breakthroughs ETF as of Q2 2026.

Based on CDKV Holdings's 13F filing for Q2 2026, filed 31 Jul 2026.